157 related articles for article (PubMed ID: 33049542)
21. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
22. Characteristics and Prognosis of Acquired Resistance to Immune Checkpoint Inhibitors in Gastrointestinal Cancer.
Zhuo N; Liu C; Zhang Q; Li J; Zhang X; Gong J; Lu M; Peng Z; Zhou J; Wang X; Jiao X; Wang Y; Wang Y; Gao M; Shen L; Lu Z
JAMA Netw Open; 2022 Mar; 5(3):e224637. PubMed ID: 35348710
[TBL] [Abstract][Full Text] [Related]
23. Local Thermal Ablation with Continuous EGFR Tyrosine Kinase Inhibitors for EGFR-Mutant Non-small Cell Lung Cancers that Developed Extra-Central Nervous System (CNS) Oligoprogressive Disease.
Ni Y; Liu B; Ye X; Fan W; Bi J; Yang X; Huang G; Li W; Wang J; Han X; Wei Z; Meng M
Cardiovasc Intervent Radiol; 2019 May; 42(5):693-699. PubMed ID: 30701290
[TBL] [Abstract][Full Text] [Related]
24. The Emerging Role of Surgery for Patients With Advanced Melanoma Treated With Immunotherapy.
Puza CJ; Bressler ES; Terando AM; Howard JH; Brown MC; Hanks B; Salama AKS; Beasley GM
J Surg Res; 2019 Apr; 236():209-215. PubMed ID: 30694757
[TBL] [Abstract][Full Text] [Related]
25. Stereotactic and Hypofractionated Radiotherapy Associated With Immune Checkpoint Inhibitor Drugs: Analysis of Local Control, Toxicity, and Outcome in a Single Research Centre Case Study.
Anzellini D; DE Sanctis V; Valeriani M; Reverberi C; Marinelli L; Massaro M; Vullo G; Facondo G; Sigillo RC; Tosi E; Osti MF
Anticancer Res; 2021 Oct; 41(10):5107-5116. PubMed ID: 34593461
[TBL] [Abstract][Full Text] [Related]
26. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Friedes C; Yegya-Raman N; Zhang S; Iocolano M; Cohen RB; Aggarwal C; Thompson JC; Marmarelis ME; Levin WP; Cengel KA; Ciunci CA; Singh AP; D'Avella C; Davis CW; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2024 Jan; 25(1):50-60.e6. PubMed ID: 37813713
[TBL] [Abstract][Full Text] [Related]
27. Bombarding Oligoprogression: Oncologic Outcomes After Radiation to Patients With Oligoprogressive Non-Small Cell Lung Cancer on Maintenance Systemic Therapy.
Chou B; Lee JH; Saetern L; Venkatesulu BP; Welsh JS; Harkenrider MM
Am J Clin Oncol; 2024 Apr; 47(4):155-160. PubMed ID: 38193499
[TBL] [Abstract][Full Text] [Related]
28. Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria.
Matos I; Martin-Liberal J; García-Ruiz A; Hierro C; Ochoa de Olza M; Viaplana C; Azaro A; Vieito M; Braña I; Mur G; Ros J; Mateos J; Villacampa G; Berché R; Oliveira M; Alsina M; Elez E; Oaknin A; Muñoz-Couselo E; Carles J; Felip E; Rodón J; Tabernero J; Dienstmann R; Perez-Lopez R; Garralda E
Clin Cancer Res; 2020 Apr; 26(8):1846-1855. PubMed ID: 31757877
[TBL] [Abstract][Full Text] [Related]
29. Oligoprogression in Metastatic, Castrate-Resistant Prostate Cancer-Prevalence and Current Clinical Practice.
Patel PH; Tunariu N; Levine DS; de Bono JS; Eeles RA; Khoo V; Murray J; Parker CC; Pathmanathan A; Reid A; van As N; Tree AC
Front Oncol; 2022; 12():862995. PubMed ID: 35656509
[TBL] [Abstract][Full Text] [Related]
30. Switch to checkpoint inhibition after targeted therapy at time of progression or during ongoing response: A retrospective single-centre experience in patients with BRAF-mutated melanoma.
Reijers ILM; Rozeman EA; Wilgenhof S; van Thienen JV; Haanen JBAG; Blank CU
Pigment Cell Melanoma Res; 2020 May; 33(3):498-506. PubMed ID: 31646741
[TBL] [Abstract][Full Text] [Related]
31. Stereotactic body radiotherapy for oligoprogression with or without switch of systemic therapy.
Willmann J; Vlaskou Badra E; Adilovic S; Ahmadsei M; Christ SM; Tanadini-Lang S; Mayinger M; Guckenberger M; Andratschke N
Clin Transl Radiat Oncol; 2024 Mar; 45():100748. PubMed ID: 38433950
[TBL] [Abstract][Full Text] [Related]
32. Immune checkpoint inhibition for pediatric patients with recurrent/refractory CNS tumors: a single institution experience.
Cacciotti C; Choi J; Alexandrescu S; Zimmerman MA; Cooney TM; Chordas C; Clymer J; Chi S; Yeo KK
J Neurooncol; 2020 Aug; 149(1):113-122. PubMed ID: 32627129
[TBL] [Abstract][Full Text] [Related]
33. A real-world data of Immune checkpoint inhibitors in solid tumors from India.
Noronha V; Abraham G; Patil V; Joshi A; Menon N; Mahajan A; Janu A; Jain S; Talreja VT; Kapoor A; Kumar Singh G; Khaddar S; Gupta K; Rathinasamy N; Srinivas S; Agrawal A; Ventrapati P; Prabhash K
Cancer Med; 2021 Mar; 10(5):1525-1534. PubMed ID: 33591635
[TBL] [Abstract][Full Text] [Related]
34. Role of Checkpoint Inhibition in Localized Bladder Cancer.
Hahn NM; Necchi A; Loriot Y; Powles T; Plimack ER; Sonpavde G; Roupret M; Kamat AM
Eur Urol Oncol; 2018 Aug; 1(3):190-198. PubMed ID: 31102620
[TBL] [Abstract][Full Text] [Related]
35. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
36. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
37. The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma.
Guida M; Bartolomeo N; De Risi I; Fucci L; Armenio A; Filannino R; Ruggieri E; Macina F; Traversa M; Nardone A; Figliuolo F; De Luca F; Mele F; Tommasi S; Strippoli S
Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31615127
[No Abstract] [Full Text] [Related]
38. Safety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter study.
Martinez Chanza N; Xie W; Issa M; Dzimitrowicz H; Tripathi A; Beuselinck B; Lam E; Zakharia Y; Mckay R; Shah S; Mortazavi A; R Harrison M; Sideris S; Kaymakcalan MD; Abou Alaiwi S; Nassar AH; Nuzzo PV; Hamid A; K Choueiri T; C Harshman L
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217762
[TBL] [Abstract][Full Text] [Related]
39. The Role of Radiotherapy in Epidermal Growth Factor Receptor Mutation-positive Patients with Oligoprogression: A Matched-cohort Analysis.
Chan OSH; Lee VHF; Mok TSK; Mo F; Chang ATY; Yeung RMW
Clin Oncol (R Coll Radiol); 2017 Sep; 29(9):568-575. PubMed ID: 28499791
[TBL] [Abstract][Full Text] [Related]
40. Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors.
Li J; Deng Y; Zhang W; Zhou AP; Guo W; Yang J; Yuan Y; Zhu L; Qin S; Xiang S; Lu H; Gong J; Xu T; Liu D; Shen L
J Hematol Oncol; 2021 Jun; 14(1):95. PubMed ID: 34154614
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]